Otsuka (4578) M&A announcement summary

Deal rationale and strategic fit

• Acquisition targets a biotech developing rapid-acting treatments for neuropsychiatric diseases, enhancing the late-stage psychiatric and CNS portfolio.

• Expands options in treatment-resistant depression and PTSD, leveraging 25 years of CNS commercialization and development experience.

• Aligns with a strategy to diversify mechanisms of action and ensure continuity and timing in business growth.

• Addresses high unmet needs in PTSD and treatment-resistant depression, aiming for a paradigm shift in psychiatric care.

• Builds on an established U.S. psychiatry platform to maximize value and reach more patients.

Financial terms and conditions

• $700 million upfront payment for 100% equity acquisition via subsidiary.

• Additional conditional milestone payments up to $525 million based on product sales performance.

Synergies and expected cost savings

• Leverages established commercial and clinical development platforms and psychiatric business infrastructure to maximize asset value.

• Utilizes expertise from over 25 years in global psychiatry and US market experience since 2002 to streamline integration and development.